Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 19 |
| Active Pipeline (Recruiting Now) | 13 (7) |
| Completed vs Stopped Early | 1 / 0 (0.0%) |
| Median Closed Actual Enrollment | 60 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Guangdong Provincial People's Hospital | Guangzhou | 3 |
| The Second Affiliated Hospital of Nanchang University | Nanchang, Jiangxi | 2 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05536505 | Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC | Phase II | RECRUITING |
| NCT07198841 | IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation | Phase II | RECRUITING |
| NCT04768075 | Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC | Phase III | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Guangdong Association of Clinical Trials Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.